GSK.L : Summary for GLAXOSMITHKLINE PLC ORD 25P - Yahoo Finance

U.S. Markets open in 5 hrs 32 mins

GlaxoSmithKline plc (GSK.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,682.50+5.50 (+0.33%)
As of 8:42AM BST. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close1,677.00
Bid1,682.00 x 175400
Ask1,682.50 x 417900
Day's Range1,681.00 - 1,689.50
52 Week Range1,363.00 - 1,745.56
Avg. Volume7,896,862
Market Cap81.67B
PE Ratio (TTM)90.46
Earnings DateN/A
Dividend & Yield1.01 (4.89%)
Ex-Dividend DateN/A
1y Target EstN/A
  • The Wall Street Journal4 hours ago

    [$$] FDA Nominee Plans Recusals From Decisions on Many Drug Firms

    President Donald Trump’s pick to lead the Food and Drug Administration plans to recuse himself for a year from agency decisions on more than 20 companies—including several drug giants.

  • Reuters14 hours ago

    FDA approves Regeneron, Sanofi $37,000 per year eczema drug

    The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies. Sanofi and Regeneron said the drug, Dupixent, will have a list price of $37,000 a year. Sanofi said is has been encouraged by conversations with health plans and pharmacy benefit managers about patient coverage for Dupixent.

  • Market Realist17 hours ago

    GlaxoSmithKline’s Segment-Wise Performance in 2016

    GSK's Consumer Health revenues increased ~9% during 2016 to ~7.2 billion pounds. The increase was mainly due to the Wellness and Skin Health franchise.